Reproducible, quantitative, and flexible molecular subtyping of clinical DLBCL samples using the NanoString nCounter system

Clinical Cancer Research

Volumn 21, Issue 10, 2015, Pages 2367-2378

  Veldman Jones, Margaret H ^a   Lai, Zhongwu ^a   Wappett, Mark ^a   Harbron, Chris G ^a   Barrett, J Carl ^a   Harrington, Elizabeth A ^a   Thress, Kenneth S ^a  

^a ASTRAZENECA   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

FOSTAMATINIB; TRANSCRIPTOME; TUMOR MARKER;

ANALYTICAL EQUIPMENT; ARTICLE; CANCER RECURRENCE; CLINICAL TRIAL; CONTROLLED STUDY; GENE EXPRESSION; GENE EXPRESSION ASSAY; GENE EXPRESSION PROFILING; GENE EXPRESSION SYSTEM; HUMAN; HUMAN TISSUE; LARGE CELL LYMPHOMA; MICROARRAY ANALYSIS; MOLECULAR TYPING; NUCLEASE PROTECTION ASSAY; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; SCORING SYSTEM; GENETICS; LYMPHOMA, LARGE B-CELL, DIFFUSE; METABOLISM; MOLECULAR DIAGNOSIS; PROCEDURES; REPRODUCIBILITY; TUMOR CELL LINE;

BIOMARKERS, TUMOR; CELL LINE, TUMOR; GENE EXPRESSION PROFILING; HUMANS; LYMPHOMA, LARGE B-CELL, DIFFUSE; MOLECULAR DIAGNOSTIC TECHNIQUES; REPRODUCIBILITY OF RESULTS; TRANSCRIPTOME;

EID: 84941947871     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-14-0357     Document Type: Article

References (40)

1. Shaffer AL III, Young RM, Staudt LM. Pathogenesis of human B cell lymphomas. Annu Rev Immunol 2012;30:565-610.
2. Bea S, Zettl A, Wright G, Salaverria I, Jehn P, Moreno V, et al. Diffuse large Bcell lymphoma subgroups have distinct genetic profiles that influence tumor biology and improve gene-expression-based survival prediction. Blood 2005;106:3183-90.
3. Alizadeh AA, Eisen MB, Davis RE, Ma C, Lossos IS, Rosenwald A, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 2000;403:503-11.
4. Wright G, Tan B, Rosenwald A, Hurt EH, Wiestner A, Staudt LM. A gene expression-based method to diagnose clinically distinct subgroups of diffuse large B cell lymphoma. Proc Natl Acad Sci U S A 2003;100: 9991-6.
5. Lenz G, Wright GW, Emre NCT, Kohlhammer H, Dave SS, Davis RE, et al. Molecular subtypes of diffuse large B-cell lymphoma arise by distinct genetic pathways. Proc Natl Acad Sci U S A 2008;105:13520-5.
6. Dunleavy K, Pittaluga S, Czuczman MS, Dave SS, Wright G, Grant N, et al. Differential efficacy of bortezomib plus chemotherapy within molecular subtypes of diffuse large B-cell lymphoma. Blood 2009;113:6069-76.
7. de Vos S, Wilson W, Gerecitano J, Goy A, Kenkre V, Barr P, et al. The Bruton's tyrosine kinase (BTK) inhibitor, ibrutinib (PCI-32765), has preferential activity in the activated B cell-like (ABC) subtype of relapse/refractory (R/R) DLBCL: interim phase 2 results [abstract]. In: Proceedings of the 18th Congress of the European Hematology Association; 2013 Jun 13-16; Stockholm, Sweden. The Hague, the Netherlands: EHA; 2013. Abstract nr S1180.
8. Zhang J, Grubor V, Love CL, Banerjee A, Richards KL, Mieczkowski PA, et al. Genetic heterogeneity of diffuse large B-cell lymphoma. Proc Natl Acad Sci U S A 2013;110:1398-403.
9. Coutinho R, Clear AJ, Owen A, Wilson A, Matthews J, Lee A, et al. Poor concordance among nine immunohistochemistry classifiers of cell-oforigin for diffuse large B-cell lymphoma: implications for therapeutic strategies. Clin Cancer Res 2013;19:6686-95.
10. Hans CP, Weisenburger DD, Greiner TC, Gascoyne RD, Delabie J, Ott G, et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood 2004;103:275-82.
11. Ott G, Ziepert M, Klapper W, Horn H, Szczepanowski M, Bernd HW, et al. Immunoblastic morphology but not the immunohistochemical GCB/nonGCB classifier predicts outcome in diffuse large B-cell lymphoma in the RICOVER-60 trial of the DSHNHL. Blood 2010;116:4916-25.
12. Roberts RA, Sabalos CM, Le Blanc ML, Martel RR, Frutiger YM, Unger JM, et al. Quantitative nuclease protection assay in paraffin-embedded tissue replicates prognostic microarray gene expression in diffuse large-B-cell lymphoma. Lab Invest 2007;87:979-97.
13. Rimsza LM, Wright G, Schwartz M, Chan WC, Jaffe ES, Gascoyne RD, et al. Accurate classification of diffuse large B-cell lymphoma into germinal center and activated B-cell subtypes using a nuclease protection assay on formalin-fixed, paraffin-embedded tissues. Clin Cancer Res 2011;17: 3727-32.
14. Beard RE, Abate-Daga D, Rosati SF, Zheng Z, Wunderlich JR, Rosenberg SA, et al. Gene expression profiling using nanostring digital RNA counting to identify potential target antigens for melanoma immunotherapy. Clin Cancer Res 2013;19:4941-50.
15. Reis PP, Waldron L, Goswami RS, Xu W, Xuan Y, Perez-Ordonez B, et al. mRNA transcript quantification in archival samples using multiplexed, color-coded probes. BMC Biotechnol 2011;11:46.
16. Northcott PA, Shih DJ, Remke M, Cho YJ, Kool M, Hawkins C, et al. Rapid, reliable, and reproducible molecular sub-grouping of clinical medulloblastoma samples. Acta Neuropathol 2012;123:615-26.
17. AstraZeneca. Study to learn if 200 mg test drug (fostamatinib) helps people with large B-cell lymphoma, a type of blood cancer [Internet]; [cited 2014 Feb 4]. Available from: http://clinicaltrials.gov/show/NCT01499303.
18. Loboda A, Nebozhyn M, Cheng C, Vessey R, Huang P, Dai H, et al. Biomarker discovery: identification of a growth factor gene signature. Clin Pharmacol Ther 2009;86:92-6.
19. Blenk S, Engelmann J, Weniger M, Schultz J, Dittrich M, Rosenwald A, et al. Germinal center B cell-like (GCB) and activated B cell-like (ABC) type of diffuse large B cell lymphoma (DLBCL): analysis of molecular predictors, signatures, cell cycle state and patient survival. Cancer Inform 2007;3:399-420.
20. Dave SS, Fu K, Wright GW, Lam LT, Kluin P, Boerma E-J, et al. Molecular Diagnosis of Burkitt's Lymphoma. N Engl J Med 2006;354:2431-42.
21. Hummel M, Bentink S, Berger H, Klapper W, Wessendorf S, Barth TFE, et al. A Biologic Definition of Burkitt's Lymphoma from Transcriptional and Genomic Profiling. N Engl J Med 2006;354:2419-30.
22. https://www.oncomine.org/resource/login.html.
23. Monti S, Savage KJ, Kutok JL, Feuerhake F, Kurtin P, Mihm M, et al. Molecular profiling of diffuse large B-cell lymphoma identifies robust subtypes including one characterized by host inflammatory response. Blood 2005;105:1851-61.
24. Ngo VN, Young RM, Schmitz R, Jhavar S, Xiao W, Lim KH, et al. Oncogenically active MYD88 mutations in human lymphoma. Nature 2011;470:115-9.
25. Naylor TL, Tang H, Ratsch BA, Enns A, Loo A, Chen L, et al. Protein kinase C inhibitor sotrastaurin selectively inhibits the growth of CD79 mutant diffuse large B-cell lymphomas. Cancer Res 2011;71:2643-53.
26. Ngo VN, Davis RE, Lamy L, Yu X, Zhao H, Lenz G, et al. A loss-of-function RNA interference screen for molecular targets in cancer. Nature 2006; 441:106-10.
27. http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSM1227194.
28. Linton K, Howarth C, Wappett M, Newton G, Lachel C, Iqbal J, et al. Microarray gene expression analysis of fixed archival tissue permits molecular classification and identification of potential therapeutic targets in diffuse large B-cell lymphoma. J Mol Diagn 2012;14:223-32.
29. Rimsza LM, Leblanc ML, Unger JM, Miller TP, Grogan TM, Persky DO, et al. Gene expression predicts overall survival in paraffin-embedded tissues of diffuse large B-cell lymphoma treated with R-CHOP. Blood 2008;112: 3425-33.
30. Southwest Oncology Group; NCI. Studying genes in samples from patients with limited or advanced diffuse large B-cell lymphoma [internet]; [cited 2014 Feb 4]. Available from: http://clinicaltrials.gov/show/NCT01563861.
31. Eastern Cooperative Oncology Group; NCI. Biomarkers in patients with diffuse large B-cell lymphoma treated with combination chemotherapy with or without rituximab [internet]; [cited 2014 Feb 4]. Available from: http://clinicaltrials.gov/show/NCT01131208.
32. Rosenwald A, Wright G, Chan WC, Connors JM, Campo E, Fisher RI, et al. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med 2002;346: 1937-47.
33. Weiss LM, Warnke RA, Sklar J, Cleary ML. Molecular analysis of the t(14;18) chromosomal translocation in malignant lymphomas. N Engl J Med 1987;317:1185-9.
34. Choi WL, Weisenburger DD, Greiner TC, et al. A new immunostain algorithm classifies diffuse large B-cell lymphoma into molecular subtypes with high accuracy. Clin Cancer Res 2009;15:5494.
35. Haarer CF, Roberts RA, Frutiger YM, Grogan TM, Rimsza LM. Immunohistochemical classification of de novo, transformed, and relapsed diffuse large B-cell lymphoma into germinal center B-cell and nongerminal center B-cell subtypes correlates with gene expression profile and patient survival. Arch Pathol Lab Med 2006;130:1819-24
36. Scott DW, Wright GW, Williams PM, Lih C-J, Walsh W, Jaffe ES, et al. Determining cell-of-origin subtypes of diffuse large B-cell lymphoma using gene expression in formalin-fixed paraffin embedded tissue. Blood 2014;123:1214-7.
37. Masque-Soler N, Szczepanowski M, Kohler CW, Spang R, Klapper W. Molecular classification of mature aggressive B-cell lymphoma using digital multiplexed gene expression on formalin-fixed paraffin-embedded biopsy specimens. Blood 2013;122:1985-6.
38. Lira ME, Kim TM, Huang D, Deng S, Koh Y, Jang B, et al. Multiplexed gene expression and fusion transcript analysis to detect ALK fusions in lung cancer. J Mol Diagn 2013;15:51-61.
39. Sun J-M, Lira M, Pandya K, Choi Y-L, Ahn JS, Mao M, et al. Clinical characteristics associated with ALK rearrangements in never-smokers with pulmonary adenocarcinoma. Lung Cancer 2014;83:259-64.
40. Iqbal J, Sanger WG, Horsman DE, Rosenwald A, Pickering DL, Dave B, et al. BCL2 translocation defines a unique tumor subsetwithin the germinal center B-cell-like diffuse large B-cell lymphoma. Am J Pathol 2004;165:159-66.